-
1
-
-
0029934215
-
Management of pulmonary disease in patients with cystic fibrosis
-
DOI 10.1056/NEJM199607183350307
-
Ramsey BW,. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996; 335: 179-188. (Pubitemid 26249456)
-
(1996)
New England Journal of Medicine
, vol.335
, Issue.3
, pp. 179-188
-
-
Ramsey, B.W.1
-
3
-
-
33144467144
-
Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines
-
DOI 10.1378/chest.129.1-suppl.250S
-
McCool FD, Rosen MJ,. Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines. Chest 2006; 129: 250S-259S. (Pubitemid 43265229)
-
(2006)
Chest
, vol.129
, Issue.SUPPL.
-
-
McCool, F.D.1
Rosen, M.J.2
-
4
-
-
66849124547
-
Cystic fibrosis pulmonary guidelines: Airway clearance therapies
-
Flume PA, Robinson KA, O'Sullivan BP, Finder JD, Vender RL, Willey-Courand DB, White TB, Marshall BC,. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009; 54: 522-537.
-
(2009)
Respir Care
, vol.54
, pp. 522-537
-
-
Flume, P.A.1
Robinson, K.A.2
O'Sullivan, B.P.3
Finder, J.D.4
Vender, R.L.5
Willey-Courand, D.B.6
White, T.B.7
Marshall, B.C.8
-
5
-
-
0028129568
-
Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis
-
DOI 10.1056/NEJM199409083311003
-
Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME,. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642. (Pubitemid 24276863)
-
(1994)
New England Journal of Medicine
, vol.331
, Issue.10
, pp. 637-642
-
-
Fuchs, H.J.1
Borowitz, D.S.2
Christiansen, D.H.3
Morris, E.M.4
Nash, M.L.5
Ramsey, B.W.6
Rosenstein, B.J.7
Smith, A.L.8
Wohl, M.E.9
-
6
-
-
30944466084
-
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis
-
DOI 10.1056/NEJMoa043900
-
Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PTP,. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354: 229-240. (Pubitemid 43113028)
-
(2006)
New England Journal of Medicine
, vol.354
, Issue.3
, pp. 229-240
-
-
Elkins, M.R.1
Robinson, M.2
Rose, B.R.3
Harbour, C.4
Moriarty, C.P.5
Marks, G.B.6
Belousova, E.G.7
Xuan, W.8
Bye, P.T.P.9
-
7
-
-
0033531143
-
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
-
DOI 10.1056/NEJM199901073400104
-
Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30. (Pubitemid 29024680)
-
(1999)
New England Journal of Medicine
, vol.340
, Issue.1
, pp. 23-30
-
-
Ramsey, B.W.1
Pepe, M.S.2
Quan, J.M.3
Otto, K.L.4
Montgomery, A.B.5
Williams-Warren, J.6
Vasiljev-K, M.7
Borowitz, D.8
Bowman, C.M.9
Marshall, B.C.10
Marshall, S.11
Smith, A.L.12
-
8
-
-
65949124667
-
Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis
-
Retsch-Bogart GZ, Quittner AL, Gibson RL, Oemann CM, McCoy KS, Montgomery AB, Cooper PJ,. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009; 135: 1223-1232.
-
(2009)
Chest
, vol.135
, pp. 1223-1232
-
-
Retsch-Bogart, G.Z.1
Quittner, A.L.2
Gibson, R.L.3
Oemann, C.M.4
McCoy, K.S.5
Montgomery, A.B.6
Cooper, P.J.7
-
9
-
-
0141816759
-
Azithromycin in Patients with Cystic Fibrosis Chronically Infected with Pseudomonas aeruginosa: A Randomized Controlled Trial
-
DOI 10.1001/jama.290.13.1749
-
Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW,. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-1756. (Pubitemid 37430625)
-
(2003)
Journal of the American Medical Association
, vol.290
, Issue.13
, pp. 1749-1756
-
-
Saiman, L.1
Marshall, B.C.2
Mayer-Hamblett, N.3
Burns, J.L.4
Quittner, A.L.5
Cibene, D.A.6
Coquillette, S.7
Fieberg, A.Y.8
Accurso, F.J.9
Campbell III, P.W.10
-
10
-
-
26944446140
-
Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis
-
DOI 10.1164/rccm.200502-218OC
-
Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, et al. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005; 172: 1008-1012. (Pubitemid 41476538)
-
(2005)
American Journal of Respiratory and Critical Care Medicine
, vol.172
, Issue.8
, pp. 1008-1012
-
-
Saiman, L.1
Mayer-Hamblett, N.2
Campbell, P.3
Marshall, B.C.4
-
11
-
-
36248953255
-
Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health
-
DOI 10.1164/rccm.200705-664OC
-
Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-969. (Pubitemid 350127838)
-
(2007)
American Journal of Respiratory and Critical Care Medicine
, vol.176
, Issue.10
, pp. 957-969
-
-
Flume, P.A.1
O'Sullivan, B.P.2
Robinson, K.A.3
Goss, C.H.4
Mogayzel Jr., P.J.5
Willey-Courand, D.B.6
Bujan, J.7
Finder, J.8
Lester, M.9
Quittell, L.10
Rosenblatt, R.11
Vender, R.L.12
Hazle, L.13
Sabadosa, K.14
Marshall, B.15
-
12
-
-
70350446684
-
Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations
-
Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC,. Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180: 802-808.
-
(2009)
Am J Respir Crit Care Med
, vol.180
, pp. 802-808
-
-
Flume, P.A.1
Mogayzel, P.J.2
Robinson, K.A.3
Goss, C.H.4
Rosenblatt, R.L.5
Kuhn, R.J.6
Marshall, B.C.7
-
13
-
-
84869499744
-
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems
-
Zobell JT, Waters CD, Young DC, Stockmann C, Ampofo K, Sherwin CM, Spigarelli, MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. Pediatr Pulmonol 2012; 47: 1147-1158.
-
(2012)
Pediatr Pulmonol
, vol.47
, pp. 1147-1158
-
-
Zobell, J.T.1
Waters, C.D.2
Young, D.C.3
Stockmann, C.4
Ampofo, K.5
Sherwin, C.M.6
Spigarelli, M.G.7
-
14
-
-
84872404132
-
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins
-
Zobell JT, Waters CD, Young DC, Stockmann C, Ampofo K, Sherwin CM, Spigarelli, MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. Pediatr Pulmonol 2013; 48: 107-122.
-
(2013)
Pediatr Pulmonol
, vol.48
, pp. 107-122
-
-
Zobell, J.T.1
Waters, C.D.2
Young, D.C.3
Stockmann, C.4
Ampofo, K.5
Sherwin, C.M.6
Spigarelli, M.G.7
-
15
-
-
84876497972
-
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones
-
et al. (in press).
-
Stockmann C, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. Pediatr Pulmonol 2012 (in press).
-
(2012)
Pediatr Pulmonol
-
-
Stockmann, C.1
-
16
-
-
84872841018
-
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium
-
Young DC, Zobell JT, Waters CD, Ampofo K, Stockmann C, Sherwin CM, Spigarelli MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium. Pediatr Pulmonol 2013; 48: 1-7.
-
(2013)
Pediatr Pulmonol
, vol.48
, pp. 1-7
-
-
Young, D.C.1
Zobell, J.T.2
Waters, C.D.3
Ampofo, K.4
Stockmann, C.5
Sherwin, C.M.6
Spigarelli, M.G.7
-
17
-
-
84878318705
-
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. aminoglycosides
-
in press
-
Young DC, Zobell JT, Stockmann C, Waters CD, Ampofo K, Sherwin CMT, Spigarelli MG,. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. aminoglycosides. Pediatr Pulmonol 2012; in press
-
(2012)
Pediatr Pulmonol
-
-
Young, D.C.1
Zobell, J.T.2
Stockmann, C.3
Waters, C.D.4
Ampofo, K.5
Sherwin, C.M.T.6
Spigarelli, M.G.7
-
18
-
-
0033773012
-
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European consensus
-
Doring G, Conway SP, Heijerman HGM, Hodson ME, Hoiby N, Smyth A, Touw DJ,. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16: 749-767.
-
(2000)
Eur Respir J
, vol.16
, pp. 749-767
-
-
Doring, G.1
Conway, S.P.2
Heijerman, H.G.M.3
Hodson, M.E.4
Hoiby, N.5
Smyth, A.6
Touw, D.J.7
-
20
-
-
77950574187
-
Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008
-
Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL,. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 2010; 45: 363-370.
-
(2010)
Pediatr Pulmonol
, vol.45
, pp. 363-370
-
-
Emerson, J.1
McNamara, S.2
Buccat, A.M.3
Worrell, K.4
Burns, J.L.5
-
21
-
-
75849154666
-
Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis
-
Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH,. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010; 45: 127-134.
-
(2010)
Pediatr Pulmonol
, vol.45
, pp. 127-134
-
-
Sanders, D.B.1
Hoffman, L.R.2
Emerson, J.3
Gibson, R.L.4
Rosenfeld, M.5
Redding, G.J.6
Goss, C.H.7
-
22
-
-
79952753579
-
Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis
-
Sanders DB, Bittner RC, Rosenfeld M, Redding, GJ, Goss CH,. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011; 46: 393-400.
-
(2011)
Pediatr Pulmonol
, vol.46
, pp. 393-400
-
-
Sanders, D.B.1
Bittner, R.C.2
Rosenfeld, M.3
Redding, G.J.4
Goss, C.H.5
-
23
-
-
77957694293
-
Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation
-
Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH,. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182: 627-632.
-
(2010)
Am J Respir Crit Care Med
, vol.182
, pp. 627-632
-
-
Sanders, D.B.1
Bittner, R.C.2
Rosenfeld, M.3
Hoffman, L.R.4
Redding, G.J.5
Goss, C.H.6
-
24
-
-
84856731944
-
Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa
-
Parkins MD, Rendall JC, Elborn JS,. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 2012; 141: 485-493.
-
(2012)
Chest
, vol.141
, pp. 485-493
-
-
Parkins, M.D.1
Rendall, J.C.2
Elborn, J.S.3
-
25
-
-
79960586834
-
Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis
-
et al.
-
de Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, Freitag A, Paterson N, Jackson M, Lougheed MD, Kumar V,. et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011; 66: 680-685.
-
(2011)
Thorax
, vol.66
, pp. 680-685
-
-
De Boer, K.1
Vandemheen, K.L.2
Tullis, E.3
Doucette, S.4
Fergusson, D.5
Freitag, A.6
Paterson, N.7
Jackson, M.8
Lougheed, M.D.9
Kumar, V.10
-
26
-
-
66149157735
-
A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis
-
Van Meter DJ, Corriveau M, Ahern JW, Lahiri T,. A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis. Pediatr Pulmonol 2009; 44: 325-329.
-
(2009)
Pediatr Pulmonol
, vol.44
, pp. 325-329
-
-
Van Meter, D.J.1
Corriveau, M.2
Ahern, J.W.3
Lahiri, T.4
-
27
-
-
80052961649
-
A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients
-
Zobell JT, Young DC, Waters CD, Ampofo K, Cash J, Marshall BC, Olson J, Chatfield BA,. A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients. Pediatr Pulmonol 2011; 46: 987-990.
-
(2011)
Pediatr Pulmonol
, vol.46
, pp. 987-990
-
-
Zobell, J.T.1
Young, D.C.2
Waters, C.D.3
Ampofo, K.4
Cash, J.5
Marshall, B.C.6
Olson, J.7
Chatfield, B.A.8
-
28
-
-
84878325359
-
National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations
-
Prescott WA, Jr., National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations. J Pediatr Pharmacol Ther 2011; 16: 262-269.
-
(2011)
J Pediatr Pharmacol Ther
, vol.16
, pp. 262-269
-
-
Prescott Jr., W.A.1
-
29
-
-
0023119430
-
Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
-
Moore RD, Lietman PS, Smith CR,. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-99. (Pubitemid 17225088)
-
(1987)
Journal of Infectious Diseases
, vol.155
, Issue.1
, pp. 93-99
-
-
Moore, R.D.1
Lietman, P.S.2
Smith, C.R.3
-
30
-
-
0012218658
-
Antimicrobial agents: The aminoglycosides
-
Limbird JGHaLE, editor. New York: McGraw-Hill;.
-
Chambers HF,. Antimicrobial agents: The aminoglycosides. In:, Limbird JGHaLE, editor. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 2001. pp 1219-1238.
-
(2001)
Goodman and Gilman's the Pharmacological Basis of Therapeutics
, pp. 1219-1238
-
-
Chambers, H.F.1
-
32
-
-
84878282305
-
Intermittent and extended-infusion Beta-Lactam utilization in cystic fibrosis
-
(in press).
-
Zobell JT, Young DC, Chatfield BA,. Intermittent and extended-infusion Beta-Lactam utilization in cystic fibrosis. Pediatr Pulmonol 2012 (in press).
-
(2012)
Pediatr Pulmonol
-
-
Zobell, J.T.1
Young, D.C.2
Chatfield, B.A.3
-
33
-
-
13844254908
-
Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - The TOPIC study: A randomised controlled trial
-
DOI 10.1016/S0140-6736(05)17906-9
-
Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, Prof Knox A,. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet 2005; 365: 573-578. (Pubitemid 40247913)
-
(2005)
Lancet
, vol.365
, Issue.9459
, pp. 573-578
-
-
Smyth, A.1
Tan, K.H.-V.2
Hyman-Taylor, P.3
Mulheran, M.4
Lewis, S.5
Stableforth, D.6
Knox, A.7
-
34
-
-
0031048805
-
Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation
-
DOI 10.1097/00006454-199701000-00033
-
Rubio TT, Miles MV, Lettieri JT, Kuhn RJ, Echols RM, Church DA,. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. Pediatr Infect Dis J 1997; 16: 112-117; discussion 123-126. (Pubitemid 27063129)
-
(1997)
Pediatric Infectious Disease Journal
, vol.16
, Issue.1
, pp. 112-117
-
-
Rubio, T.T.1
Miles, M.V.2
Lettieri, J.T.3
Kuhn, R.J.4
Echols, R.M.5
Church, D.A.6
-
35
-
-
77953915742
-
High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients
-
Zobell JT, Ampofo K, Cash J, Korgenski K, Chatfield BA,. High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. J Cyst Fibros 2010; 9: 280-283.
-
(2010)
J Cyst Fibros
, vol.9
, pp. 280-283
-
-
Zobell, J.T.1
Ampofo, K.2
Cash, J.3
Korgenski, K.4
Chatfield, B.A.5
-
36
-
-
70349155467
-
Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis
-
et al.
-
Hubert D, Le Roux E, Lavrut T, Wallaert B, Scheid P, Manach D, Grenet D, Sermet-Gaudelus I, Ramel S, Cracowski C, et al. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob Agents Chemother 2009; 53: 3650-3656.
-
(2009)
Antimicrob Agents Chemother
, vol.53
, pp. 3650-3656
-
-
Hubert, D.1
Le Roux, E.2
Lavrut, T.3
Wallaert, B.4
Scheid, P.5
Manach, D.6
Grenet, D.7
Sermet-Gaudelus, I.8
Ramel, S.9
Cracowski, C.10
-
37
-
-
0023296643
-
Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis
-
Reed MD, Stern RC, Myers CM, Klinger JD, Yamashita TS, Blumer JL,. Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 1987; 3: 101-109.
-
(1987)
Pediatr Pulmonol
, vol.3
, pp. 101-109
-
-
Reed, M.D.1
Stern, R.C.2
Myers, C.M.3
Klinger, J.D.4
Yamashita, T.S.5
Blumer, J.L.6
-
38
-
-
0024330490
-
Antipseudomonal therapy in cystic fibrosis: Aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin
-
Schaad UB, Wedgwood-Krucko J, Guenin K, Buehlmann U, Kraemer R,. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. Eur J Clin Microbiol Infect Dis 1989; 8: 858-865. (Pubitemid 19265870)
-
(1989)
European Journal of Clinical Microbiology and Infectious Diseases
, vol.8
, Issue.10
, pp. 858-865
-
-
Schaad, U.B.1
Wedgwood-Krucko, J.2
Guenin, K.3
Buehlmann, U.4
Kraemer, R.5
-
39
-
-
0026723491
-
A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis
-
Salh B, Bilton D, Dodd M, Abbot J, Webb K,. A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis. Scand J Infect Dis 1992; 24: 215-218.
-
(1992)
Scand J Infect Dis
, vol.24
, pp. 215-218
-
-
Salh, B.1
Bilton, D.2
Dodd, M.3
Abbot, J.4
Webb, K.5
-
40
-
-
40649105285
-
Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis
-
DOI 10.1016/j.jcf.2007.07.001, PII S1569199307000926
-
Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler M, Griese M,. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. J Cyst Fibros 2008; 7: 142-146. (Pubitemid 351372759)
-
(2008)
Journal of Cystic Fibrosis
, vol.7
, Issue.2
, pp. 142-146
-
-
Latzin, P.1
Fehling, M.2
Bauernfeind, A.3
Reinhardt, D.4
Kappler, M.5
Griese, M.6
-
41
-
-
27144479200
-
The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis
-
DOI 10.1378/chest.128.4.2336
-
Blumer JL, Saiman L, Konstan MW, Melnick D,. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005; 128: 2336-2346. (Pubitemid 41507577)
-
(2005)
Chest
, vol.128
, Issue.4
, pp. 2336-2346
-
-
Blumer, J.L.1
Saiman, L.2
Konstan, M.W.3
Melnick, D.4
-
42
-
-
78650185664
-
Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis
-
Guillot E, Sermet I, Ferroni A, Chhun S, Pons G, Zahar JR, Jullien V,. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis. Pharmacotherapy 2010; 30: 1252-1258.
-
(2010)
Pharmacotherapy
, vol.30
, pp. 1252-1258
-
-
Guillot, E.1
Sermet, I.2
Ferroni, A.3
Chhun, S.4
Pons, G.5
Zahar, J.R.6
Jullien, V.7
-
43
-
-
0031783802
-
Drug disposition in cystic fibrosis
-
DOI 10.2165/00003088-199835040-00004
-
Rey E, Treluyer JM, Pons G,. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998; 35: 313-329. (Pubitemid 28491216)
-
(1998)
Clinical Pharmacokinetics
, vol.35
, Issue.4
, pp. 313-329
-
-
Rey, E.1
Treluyer, J.-M.2
Pons, G.3
-
44
-
-
0022117320
-
Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis
-
Mann HJ, Canafax DM, Cipolle RJ, Daniels CE, Zaske DE, Warwick WJ,. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis. Pediatr Pulmonol 1985; 1: 238-243.
-
(1985)
Pediatr Pulmonol
, vol.1
, pp. 238-243
-
-
Mann, H.J.1
Canafax, D.M.2
Cipolle, R.J.3
Daniels, C.E.4
Zaske, D.E.5
Warwick, W.J.6
-
45
-
-
0023555047
-
Drug disposition in cystic fibrosis: Progress in understanding pathophysiology and pharmacokinetics
-
Prandota J,. Drug disposition in cystic fibrosis: progress in understanding pathophysiology and pharmacokinetics. Pediatr Infect Dis J 1987; 6: 1111-1126. (Pubitemid 18029589)
-
(1987)
Pediatric Infectious Disease Journal
, vol.6
, Issue.12
, pp. 1111-1126
-
-
Prandota, J.1
-
46
-
-
0025166486
-
Pharmacokinetics of ticarcillin in patients with cystic fibrosis: A controlled prospective study
-
de Groot R, Hack BD, Weber A, Chaffin D, Ramsey B, Smith AL,. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a controlled prospective study. Clin Pharmacol Ther 1990; 47: 73-78. (Pubitemid 20041213)
-
(1990)
Clinical Pharmacology and Therapeutics
, vol.47
, Issue.1
, pp. 73-78
-
-
De Groot, R.1
Hack, B.D.2
Weber, A.3
Chaffin, D.4
Ramsey, B.5
Smith, A.L.6
-
47
-
-
0023205584
-
High dose treatment with antibiotics in cystic fibrosis - A reappraisal with special reference to the pharmacokinetics of betalactams and new fluoroquinolones in adult CF-patients
-
DOI 10.1007/BF01647751
-
Sorgel F, Stephan U, Wiesemann HG, Gottschalk B, Stehr C, Rey M, Bowing HB, Dominick HC, Geldmacher von Mallinckrodt M,. High dose treatment with antibiotics in cystic fibrosis-a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients. Infection 1987; 15: 385-396. (Pubitemid 17156117)
-
(1987)
Infection
, vol.15
, Issue.5
, pp. 385-396
-
-
Sorgel, F.1
Stephan, U.2
Wiesemann, H.G.3
Gottschalk, B.4
Stehr, C.5
Rey, M.6
Bowing, H.B.7
Dominick, H.C.8
Geldmacher Von Mallinckrodt, M.9
-
48
-
-
0031874587
-
Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis
-
DOI 10.1023/A:1008634911114
-
Touw DJ,. Clinical pharmacokinetics, of antimicrobial, drugs in, cystic fibrosis. Pharm World Sci 1998; 20: 149-160. (Pubitemid 28393870)
-
(1998)
Pharmacy World and Science
, vol.20
, Issue.4
, pp. 149-160
-
-
Touw, D.J.1
-
49
-
-
0032433579
-
Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions
-
DOI 10.2165/00003088-199835060-00003
-
Touw DJ, Vinks AA, Mouton JW, Horrevorts, AM,. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions. Clin Pharmacokinet 1998; 35: 437-459. (Pubitemid 29010175)
-
(1998)
Clinical Pharmacokinetics
, vol.35
, Issue.6
, pp. 437-459
-
-
Touw, D.J.1
Vinks, A.A.T.M.M.2
Mouton, J.W.3
Horrevorts, A.M.4
-
50
-
-
0030068223
-
Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients
-
Schaefer HG, Stass H, Wedgwood J, Hampel B, Fischer C, Kuhlmann J, Schaad UB,. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. Antimicrob Agents Chemother 1996; 40: 29-34. (Pubitemid 26019673)
-
(1996)
Antimicrobial Agents and Chemotherapy
, vol.40
, Issue.1
, pp. 29-34
-
-
Schaefer, H.G.1
Stass, H.2
Wedgwood, J.3
Hampel, B.4
Fischer, C.5
Kuhlmann, J.6
Schaad, U.B.7
-
51
-
-
33847753552
-
Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis-caution with trough concentrations
-
DOI 10.1016/j.jcf.2006.05.015, PII S1569199306000907
-
Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J,. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis-caution with trough concentrations. J Cyst Fibros 2007; 6: 125-130. (Pubitemid 46381653)
-
(2007)
Journal of Cystic Fibrosis
, vol.6
, Issue.2
, pp. 125-130
-
-
Coulthard, K.P.1
Peckham, D.G.2
Conway, S.P.3
Smith, C.A.4
Bell, J.5
Turnidge, J.6
-
52
-
-
0035177895
-
Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: Simple or complex pharmacokinetic methods?
-
Tod MM, Padoin C, Petitjean O,. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods? Clin Pharmacokinet 2001; 40: 803-814. (Pubitemid 33095997)
-
(2001)
Clinical Pharmacokinetics
, vol.40
, Issue.11
, pp. 803-814
-
-
Tod, M.M.1
Padoin, C.2
Petitjean, O.3
-
53
-
-
33846573411
-
Impact of pharmacometric reviews on new drug approval and labeling decisions - A survey of 31 new drug applications submitted between 2005 and 2006
-
DOI 10.1038/sj.clpt.6100051, PII 6100051
-
Bhattaram VA, Bonapace C, Chilukuri DM, Duan JZ, Garnett C, Gobburu JV, Jang SH, Kenna L, Lesko LJ, Madabushi R, et al. Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther 2007; 81: 213-221. (Pubitemid 46174818)
-
(2007)
Clinical Pharmacology and Therapeutics
, vol.81
, Issue.2
, pp. 213-221
-
-
Bhattaram, V.A.1
Bonapace, C.2
Chilukuri, D.M.3
Duan, J.Z.4
Garnett, C.5
Gobburu, J.V.S.6
Jang, S.H.7
Kenna, L.8
Lesko, L.J.9
Madabushi, R.10
Men, Y.11
Powell, J.R.12
Qiu, W.13
Ramchandani, R.P.14
Tornoe, C.W.15
Wang, Y.16
Zheng, J.J.17
-
54
-
-
34250632673
-
Introduction of quantitative methods in pharmacology and clinical pharmacology: A historical overview
-
DOI 10.1038/sj.clpt.6100248, PII 6100248
-
Atkinson AJ, Jr., Lalonde RL,. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview. Clin Pharmacol Ther 2007; 82: 3-6. (Pubitemid 46944206)
-
(2007)
Clinical Pharmacology and Therapeutics
, vol.82
, Issue.1
, pp. 3-6
-
-
Atkinson Jr., A.J.1
Lalonde, R.L.2
-
55
-
-
34250749661
-
Model-based drug development
-
DOI 10.1038/sj.clpt.6100235, PII 6100235
-
Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall SA, Benincosa, LJ, et al. Model-based drug development. Clin Pharmacol Ther 2007; 82: 21-32. (Pubitemid 46950619)
-
(2007)
Clinical Pharmacology and Therapeutics
, vol.82
, Issue.1
, pp. 21-32
-
-
Lalonde, R.L.1
Kowalski, K.G.2
Hutmacher, M.M.3
Ewy, W.4
Nichols, D.J.5
Milligan, P.A.6
Corrigan, B.W.7
Lockwood, P.A.8
Marshall, S.A.9
Benincosa, L.J.10
Tensfeldt, T.G.11
Parivar, K.12
Amantea, M.13
Glue, P.14
Koide, H.15
Miller, R.16
-
56
-
-
34250658781
-
Getting the dose right": Facts, a blueprint, and encouragements
-
Peck CC, Cross JT,. " Getting the dose right": facts, a blueprint, and encouragements. Clin Pharmacol Ther 2007; 82: 12-14.
-
(2007)
Clin Pharmacol Ther
, vol.82
, pp. 12-14
-
-
Peck, C.C.1
Cross, J.T.2
-
57
-
-
18844452358
-
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: An update
-
DOI 10.1093/jac/dki079
-
Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL,. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55: 601-607. (Pubitemid 40691835)
-
(2005)
Journal of Antimicrobial Chemotherapy
, vol.55
, Issue.5
, pp. 601-607
-
-
Mouton, J.W.1
Dudley, M.N.2
Cars, O.3
Derendorf, H.4
Drusano, G.L.5
-
58
-
-
13244281964
-
Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: The minimum inhibitory concentration versus stationary concentration
-
DOI 10.2165/00003088-200544020-00005
-
Mouton JW, Vinks AA,. Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet 2005; 44: 201-210. (Pubitemid 40188941)
-
(2005)
Clinical Pharmacokinetics
, vol.44
, Issue.2
, pp. 201-210
-
-
Mouton, J.W.1
Vinks, A.A.2
-
59
-
-
77949365122
-
-
FAO/WHO/OIE Rome, Italy, 26-30 November 2007. FAO, Rome, Italy, and WHO, Geneva, Switzerland
-
FAO/WHO/OIE. 2008. Joint FAO/WHO/OIE Expert Meeting on Critically Important Antimicrobials. Report of a meeting held in FAO, Rome, Italy, 26-30 November 2007. FAO, Rome, Italy, and WHO, Geneva, Switzerland.
-
(2008)
Joint FAO/WHO/OIE Expert Meeting on Critically Important Antimicrobials. Report of A Meeting Held in FAO
-
-
-
63
-
-
0031952586
-
Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
-
quiz 11-12.
-
Craig WA,. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-12.
-
(1998)
Clin Infect Dis
, vol.26
, pp. 1-10
-
-
Craig, W.A.1
-
64
-
-
13944278028
-
Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections
-
DOI 10.1086/426189
-
Burgess DS,. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis 2005; 40: S99-S104. (Pubitemid 40270207)
-
(2005)
Clinical Infectious Diseases
, vol.40
, Issue.SUPPL.
-
-
Burgess, D.S.1
-
65
-
-
0032701245
-
Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside
-
Murry KR, McKinnon PS, Mitrzyk B, Rybak MJ,. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy 1999; 19: 1252-1260.
-
(1999)
Pharmacotherapy
, vol.19
, pp. 1252-1260
-
-
Murry, K.R.1
McKinnon, P.S.2
Mitrzyk, B.3
Rybak, M.J.4
-
66
-
-
0021708980
-
Role for dual individualization with cefmenoxime
-
Schentag JJ, Smith IL, Swanson DJ, DeAngelis C, Fracasso JE, Vari A, Vance JW,. Role for dual individualization with cefmenoxime. Am J Med 1984; 77: 43-50. (Pubitemid 15153297)
-
(1984)
American Journal of Medicine
, vol.77
, Issue.6
, pp. 43-50
-
-
Schentag, J.J.1
Smith, I.L.2
Swanson, D.J.3
-
69
-
-
0018935088
-
Use of piperacillin, a semisynthetic penicillin, in the therapy of acute exacerbations of pulmonary disease in patients with cystic fibrosis
-
Prince AS, Neu HC,. Use of piperacillin, a semisynthetic penicillin, in the therapy of acute exacerbations of pulmonary disease in patients with cystic fibrosis. J Pediatr 1980; 97: 148-151. (Pubitemid 10033787)
-
(1980)
Journal of Pediatrics
, vol.97
, Issue.1
, pp. 148-151
-
-
Prince, A.S.1
Neu, H.C.2
-
70
-
-
0023675683
-
Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis
-
McCarty JM, Tilden SJ, Black P, Craft JC, Blumer J, Waring W, Halsey NA,. Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis. Pediatr Pulmonol 1988; 4: 201-204.
-
(1988)
Pediatr Pulmonol
, vol.4
, pp. 201-204
-
-
McCarty, J.M.1
Tilden, S.J.2
Black, P.3
Craft, J.C.4
Blumer, J.5
Waring, W.6
Halsey, N.A.7
-
71
-
-
34447262551
-
Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers
-
DOI 10.1128/AAC.01477-06
-
Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, Sorgel F,. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007; 51: 2497-2507. (Pubitemid 47047329)
-
(2007)
Antimicrobial Agents and Chemotherapy
, vol.51
, Issue.7
, pp. 2497-2507
-
-
Bulitta, J.B.1
Duffull, S.B.2
Kinzig-Schippers, M.3
Holzgrabe, U.4
Stephan, U.5
Drusano, G.L.6
Sorgel, F.7
-
83
-
-
84878314029
-
-
Ortho-McNeil-Janssen Pharmaceuticals, Inc.
-
Levaquin® Approved Package labeling, 2011, Ortho-McNeil-Janssen Pharmaceuticals, Inc.
-
(2011)
Levaquin® Approved Package Labeling
-
-
|